MX2020011614A - Anticuerpos con perfiles de glicanos modulados. - Google Patents

Anticuerpos con perfiles de glicanos modulados.

Info

Publication number
MX2020011614A
MX2020011614A MX2020011614A MX2020011614A MX2020011614A MX 2020011614 A MX2020011614 A MX 2020011614A MX 2020011614 A MX2020011614 A MX 2020011614A MX 2020011614 A MX2020011614 A MX 2020011614A MX 2020011614 A MX2020011614 A MX 2020011614A
Authority
MX
Mexico
Prior art keywords
antibodies
modulated
glycan profiles
profiles
glycan
Prior art date
Application number
MX2020011614A
Other languages
English (en)
Inventor
Christopher Kenyon Crowell
Jian Wu
Athena Denise Nagi
Neil Anthony Kitchen
Alison Jean Gillespie
Simina Crina Petrovan
Michael Charles Brandenstein
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2020011614A publication Critical patent/MX2020011614A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta invención se refiere a moléculas de denosumab expresadas de manera recombinante y a métodos para modular los perfiles de glicanos de las moléculas de denosumab.
MX2020011614A 2018-05-01 2019-04-30 Anticuerpos con perfiles de glicanos modulados. MX2020011614A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862665045P 2018-05-01 2018-05-01
PCT/US2019/029850 WO2019213043A1 (en) 2018-05-01 2019-04-30 Antibodies with modulated glycan profiles

Publications (1)

Publication Number Publication Date
MX2020011614A true MX2020011614A (es) 2020-12-09

Family

ID=66542532

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011614A MX2020011614A (es) 2018-05-01 2019-04-30 Anticuerpos con perfiles de glicanos modulados.

Country Status (16)

Country Link
US (1) US12084686B2 (es)
EP (2) EP3788076A1 (es)
JP (1) JP7536651B2 (es)
KR (1) KR20210005689A (es)
CN (1) CN112074537A (es)
AU (1) AU2019263008A1 (es)
BR (1) BR112020022166A2 (es)
CA (1) CA3099163A1 (es)
CL (1) CL2020002810A1 (es)
EA (1) EA202092576A1 (es)
IL (2) IL307155A (es)
MA (1) MA52490A (es)
MX (1) MX2020011614A (es)
SG (1) SG11202010744YA (es)
TW (1) TW202003574A (es)
WO (1) WO2019213043A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR129727A1 (es) * 2022-06-28 2024-09-25 Amgen Inc Configuraciones flexibles de instalaciones para la fabricación de productos terapéuticos
CN117825686A (zh) * 2024-03-05 2024-04-05 军科正源（北京）药物研究有限责任公司 用于检测地诺单抗抗药性抗体的样品预处理方法及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US159259A (en) * 1875-02-02 Improvement in reservoir cooking-stoves
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4499064A (en) 1982-06-03 1985-02-12 Clayton Foundation For Research Assessment of nutritional status of individuals
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
JPH06292592A (ja) 1993-02-09 1994-10-21 Snow Brand Milk Prod Co Ltd 糖蛋白質の生産方法
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
EP0835305B1 (en) 1995-06-29 2005-11-23 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DK1036179T4 (da) 1997-12-03 2014-03-31 Roche Diagnostics Gmbh Fremgangsmåde til fremstilling af polypeptider med egnet glycosilering
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PT1543106E (pt) 2002-07-15 2007-05-31 Immunex Corp Métodos e meios para controlar a sialilação de proteínas produzidas por células de mamíferos
ATE488600T1 (de) 2002-12-23 2010-12-15 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7691611B2 (en) 2005-06-03 2010-04-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR102558247B1 (ko) 2011-07-01 2023-07-24 암젠 인크 포유동물 세포 배양
WO2013181575A2 (en) * 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to denosumab
US8956830B2 (en) * 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI625390B (zh) * 2013-03-14 2018-06-01 安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
WO2015009259A2 (en) * 2013-07-19 2015-01-22 Kaynakli Ömer A simple ripper for roll papers
US11427627B2 (en) 2013-09-05 2022-08-30 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
MX2016005572A (es) 2013-10-31 2016-12-09 Amgen Inc Uso de monensina para regular la glicosilacion de proteinas recombinantes.
KR102519540B1 (ko) 2014-01-29 2023-04-10 암젠 인크 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현

Also Published As

Publication number Publication date
JP2021521854A (ja) 2021-08-30
IL307155A (en) 2023-11-01
EP4316519A3 (en) 2024-04-24
EA202092576A1 (ru) 2021-02-05
WO2019213043A1 (en) 2019-11-07
SG11202010744YA (en) 2020-11-27
TW202003574A (zh) 2020-01-16
CL2020002810A1 (es) 2021-02-19
CN112074537A (zh) 2020-12-11
CA3099163A1 (en) 2019-11-07
IL278211B1 (en) 2023-10-01
EP4316519A2 (en) 2024-02-07
MA52490A (fr) 2021-03-10
KR20210005689A (ko) 2021-01-14
BR112020022166A2 (pt) 2021-01-26
EP3788076A1 (en) 2021-03-10
US12084686B2 (en) 2024-09-10
US20210062156A1 (en) 2021-03-04
IL278211A (en) 2020-11-30
JP7536651B2 (ja) 2024-08-20
AU2019263008A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
PH12019502283A1 (en) Anti-lag3 antibodies
PH12019502282A1 (en) Bispecific antibodies specifically binding to pd1 and lag3
EA201992497A1 (ru) МОДУЛЯТОРЫ K-Ras
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
AU2016320748A8 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
AU2018281045A1 (en) Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
EP4219561A3 (en) Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
PH12020550243A1 (en) Anti-tau antibodies and uses thereof
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EP3856785A4 (en) ANTIGEN-BINDING MOLECULES ABLE TO BIND TO CD3 AND CD137 BUT NOT SIMULTANEOUSLY
NZ732628A (en) Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
EP4420727A3 (en) Bispecific egfr/c-met antibodies
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
WO2016090278A3 (en) Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
MX2023010076A (es) Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
WO2018106776A3 (en) Anti-tau antibodies and methods of their use
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
MX2019011585A (es) Anticuerpos miltiespecificos estables.
MX2016012273A (es) Proteinas de union al antigeno vl que presentan diferentes caracteristicas de union.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d